You are here

Article Text

Article menu
Download PDFPDF
Letter
A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis
  1. Ndiémé Ndongo-Thiam,
  2. Pierre Miossec
  1. Immunogenomics and Inflammation Research Unit and the Department of Clinical Immunology and Rheumatology, Hospices Civils de Lyon, EA 4130 University of Lyon 1, Hôpital Edouard Herriot, Lyon, France
  1. Correspondence to Professor P Miossec, Department of Clinical Immunology and Rheumatology, Hôpital Edouard Herriot, Lyon 69437, Cedex 03, France; miossec{at}univ-lyon1.fr

https://doi.org/10.1136/annrheumdis-2014-207110

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Interleukin 17 (IL-17) plays an important role in many chronic inflammatory diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis (RA).1 Measuring circulating IL-17 levels could be crucial to identifying patients who would benefit from IL-17-targeted therapies.2 Detection by ELISA has been difficult with high variability between studies. Furthermore, IL-17 function is critical to taking into consideration the contribution of activators (eg, tumour necrosis factor (TNF)-α acting in synergy with IL-17) and inhibitors (IL-25, autoantibodies).

    In previous studies, human umbilical vein endothelial cells (HUVEC) were shown to be highly sensitive to IL-17 stimulation for the production of the chemokine IL-8.3 These cells were thus used in a functional bioassay to measure circulating bioactive IL-17. To determine the contribution of IL-17 in the IL-8-inducing activity, plasma samples at the dilution of 10% were first preincubated with or without an anti-IL-17 antibody at 10 µg/mL (R&D systems, Paris, France), before being added to HUVEC (see more details in figure 1 legend and in figure 1A, B). After 48 h of incubation, IL-8 production was measured in supernatants …

    View Full Text

    Footnotes

    • Contributors NN-T: experiments and writing; PM: concept and writing.

    • Funding NN-T is supported by the IHU prometteur OPERA. PM is a senior member of and supported by the Institut Universitaire de France.

    • Competing interests NN-T and PM hold a patent on the determination of bioactive IL-17.

    • Patient consent Obtained.

    • Ethics approval Ethics committee of the hospitals of Lyon.

    • Provenance and peer review Not commissioned; externally peer reviewed.